February 13, 2020 / 12:07 PM / 4 days ago

BRIEF-Bristol-Myers - FDA Accepts For Priority Review Co's Biologics License Application (BLA) For Lymphoma Drug

Feb 13 (Reuters) - Bristol-Myers Squibb Co:

* U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS FOR PRIORITY REVIEW BRISTOL-MYERS SQUIBB’S BIOLOGICS LICENSE APPLICATION (BLA) FOR LISOCABTAGENE MARALEUCEL (LISO-CEL) FOR ADULT PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA

* BRISTOL-MYERS SQUIBB CO - FDA HAS SET A PDUFA GOAL DATE OF AUGUST 17, 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below